ERBB2 and breast cancer: In HER2-negative stage II/III BC patients treated with triple combination (durvalumab, olaparib, and chemotherapy) compared with chemotherapy alone, a higher expression of immune gene signatures and PD-L1 mRNA expression was associated with higher pathologic complete response rates [146].